Phathom Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Phathom Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q2 2024.
  • Phathom Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$77.3M, a 144% decline year-over-year.
  • Phathom Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$253M, a 67.5% decline year-over-year.
  • Phathom Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$167M, a 2.97% increase from 2022.
  • Phathom Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$172M, a 27.7% decline from 2021.
  • Phathom Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$135M, a 7.49% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$253M -$77.3M -$45.6M -144% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$207M -$70M -$39.9M -133% Jan 1, 2024 Mar 31, 2024 10-Q/A 2024-06-14
Q4 2023 -$167M -$69.9M -$23.2M -49.8% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-06-14
Q3 2023 -$144M -$35.7M +$6.87M +16.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$151M -$31.7M +$13.7M +30.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$165M -$30.1M +$7.83M +20.7% Jan 1, 2023 Mar 31, 2023 10-Q/A 2024-06-14
Q4 2022 -$172M -$46.6M -$13.6M -41.2% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-06-14
Q3 2022 -$159M -$42.5M -$9.39M -28.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$149M -$45.4M -$10M -28.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$139M -$37.9M -$4.32M -12.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$135M -$33M +$19.4M +37% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 -$154M -$33.1M -$307K -0.94% Jul 1, 2021 Sep 30, 2021 10-Q/A 2022-11-09
Q2 2021 -$154M -$35.3M -$15.3M -76.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 -$139M -$33.6M -$13.2M -64.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$126M -$52.4M -$36.7M -234% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-30
Q3 2020 -$88.9M -$32.8M -$26.5M -423% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$62.4M -$20M +$63M +75.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$125M -$20.4M -$19.1M -1562% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 -$106M -$15.7M -$15.2M -3380% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-30
Q3 2019 -$91M -$6.28M -$6.01M -2244% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-30
Q2 2019 -$85M -$83M -$82.8M -32455% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-30
Q1 2019 -$2.2M -$1.23M -$975K -388% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-30
Q4 2018 -$1.23M -$451K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-19
Q3 2018 -$268K Jul 1, 2018 Sep 30, 2018 10-K 2020-03-19
Q2 2018 -$255K Apr 1, 2018 Jun 30, 2018 10-K 2020-03-19
Q1 2018 -$251K Jan 1, 2018 Mar 31, 2018 10-K 2020-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.